New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GAITHERSBURG, Md. --(BUSINESS WIRE)--Aug. 11, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving
GAITHERSBURG, Md. --(BUSINESS WIRE)--Aug. 6, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity 46th Annual Growth
Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin (1) of 70% and adjusted net income (1) of $0.4 million Reiterating full year 2026 revenue
GAITHERSBURG, Md. --(BUSINESS WIRE)--Jul. 16, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026.
Former Quest Diagnostics leader joins to fuel operational and commercial execution GAITHERSBURG, Md. --(BUSINESS WIRE)--Jun. 16, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the appointment of Mark Gardner
GAITHERSBURG, Md. --(BUSINESS WIRE)--May 26, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June
Reported total revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome volume growth of 34% year-over-year Reported adjusted gross margin (1) of 69% and adjusted net loss (1) of $8.2 million Updating full-year 2026 revenue guidance to $475 to
GAITHERSBURG, Md. --(BUSINESS WIRE)--Apr. 13, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026.
New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GAITHERSBURG, Md.--( BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and
Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GAITHERSBURG, Md. --(BUSINESS WIRE)--Mar. 10, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today